Alpha 2.0
Login Register
» Articles » PMID: 6224683

Pharmacokinetics of Norfloxacin in Healthy Volunteers and Patients with Renal and Hepatic Damage

Overview
Journal Eur J Clin Microbiol
Specialty Microbiology
Date 1983 Jun 1
PMID 6224683
Citations 26
Authors
M Eandi
I Viano
F DI NOLA
L Leone
E GENAZZANI
Affiliations
Soon will be listed here.
Abstract

The pharmacokinetics of norfloxacin were studied in six healthy volunteers, and three patients each with moderate renal and hepatic damage. A new specific and sensitive high performance liquid chromatography method was set up to measure plasma and urine concentrations of norfloxacin. The mean urinary concentrations after a single oral dose of 400 mg norfloxacin exceeded many times the MIC and MBC values of most of the bacterial strains responsible for urinary tract infections. Results in the patients with hepatic and renal damage indicated slight and not statistically significant differences in comparison with healthy volunteers.

Citing Articles

Urine bactericidal activity of pefloxacin versus norfloxacin in healthy female volunteers after a single 800-mg oral dose.

Hofbauer H, Naber K, Kinzig-Schippers M, Sorgel F, Wiedemann B, Reiz A Infection. 1997; 25(2):121-6.

PMID: 9108190 DOI: 10.1007/BF02113592.

Clinical pharmacokinetics of newer antibacterial agents in liver disease.

Westphal J, Brogard J Clin Pharmacokinet. 1993; 24(1):46-58.

PMID: 8448972 DOI: 10.2165/00003088-199324010-00004.

Absorption interactions with fluoroquinolones. 1995 update.

Lomaestro B, Bailie G Drug Saf. 1995; 12(5):314-33.

PMID: 7669261 DOI: 10.2165/00002018-199512050-00004.

The activity of ciprofloxacin and other 4-quinolones against Chlamydia trachomatis and Mycoplasmas in vitro.

Ridgway G, Mumtaz G, Gabriel F, Oriel J Eur J Clin Microbiol. 1984; 3(4):344-6.

PMID: 6237903 DOI: 10.1007/BF01977491.

Comparative in vitro activity of five quinoline derivatives and five other antimicrobial agents used in oral therapy.

Hoogkamp-Korstanje J Eur J Clin Microbiol. 1984; 3(4):333-8.

PMID: 6237901 DOI: 10.1007/BF01977489.

References
1.
Khan M, Gruninger R, Nelson S, Klicker R . Comparative in vitro activity of norfloxacin (MK-0366) and ten other oral antimicrobial agents against urinary bacterial isolates. Antimicrob Agents Chemother. 1982; 21(5):848-51. PMC: 182027. DOI: 10.1128/AAC.21.5.848. View
2.
Neu H, Labthavikul P . In vitro activity of norfloxacin, a quinolinecarboxylic acid, compared with that of beta-lactams, aminoglycosides, and trimethoprim. Antimicrob Agents Chemother. 1982; 22(1):23-7. PMC: 183667. DOI: 10.1128/AAC.22.1.23. View
3.
Hirai K, Ito A, Abe Y, SUZUE S, IRIKURA T, Inoue M . Comparative activities of AM-715 and pipemidic and nalidixic acids against experimentally induced systemic and urinary tract infections. Antimicrob Agents Chemother. 1981; 19(1):188-9. PMC: 181380. DOI: 10.1128/AAC.19.1.188. View
4.
GADEBUSCH H, Shungu D, Weinberg E, Chung S . Comparison of the antibacterial activity of norfloxacin (MK 0366, AM 715), a new organic acid, with that of other orally absorbed chemotherapeutic agents. Infection. 1982; 10(1):41-4. DOI: 10.1007/BF01640837. View
5.
Boppana V, Swanson B . Determination of norfloxacin, a new nalidixic acid analog, in human serum and urine by high-performance liquid chromatography. Antimicrob Agents Chemother. 1982; 21(5):808-10. PMC: 182016. DOI: 10.1128/AAC.21.5.808. View